Alteration in immune function in patients with fatty liver disease
作者机构:Department of SurgeryRutgers Robert Wood Johnson Medical SchoolNew BrunswickNJ 08901USA Division of Surgical OncologyDepartment of SurgeryThe Ohio State University Wexner Medical CenterColumbusOH 43210USA
出 版 物:《Hepatoma Research》 (肝癌研究(英文版))
年 卷 期:2022年第8卷第1期
页 面:363-375页
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题:Non-alcoholic steatohepatitis nonalcoholic fatty liver disease steatohepatitis immunology hepatocellular carcinoma
摘 要:Nonalcoholic fatty liver disease(NAFLD)is a disease spectrum that spans simple steatosis,fibrosis,and ultimately cirrhosis,and is a leading cause of chronic liver disease *** severe variant of NAFLD,non-alcoholic steatohepatitis(NASH),is characterized by triglyceride accumulation within hepatocytes and the subsequent inflammatory pathway activation,ultimately progressing to cirrhosis in 10%-20%of *** is a known major risk factor for the development of hepatocellular carcinoma(HCC),and there is emerging data demonstrating the impact of NASH on immune subsets and the tumor microenvironment that may influence therapeutic *** review describes the various ways in which the immune system is altered in patients with *** innate immune system in NASH shows alterations in dendritic and Kupffer cells,impaired cytotoxicity of Natural Killer cells,and an accumulation of ***,there is emerging evidence emphasizing the role of the adaptive immune system in the development and progression of NASH,seen in the alteration of B-cells,T-cells,and NKT *** to the complex interplay of the immune system in NAFLD/NASH and its progression to HCC,many current treatments focus on targeting immune cells for HCC ***,immune checkpoint inhibitors such as atezolizumab and bevacizumab have been approved as first-line therapy for unresectable *** an emerging field of research,further studies and clinical trials are needed to understand the complex interface of NASH,HCC and the immune response.